Oxygen Desaturation During a 6-minute Walk Test As a Predictor of Maximal Exercise-induced Gas Exchange Abnormalities in Sarcoidosis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2016 Sep 14

PMID 27621852

Citations 4

Authors

Cecile Chenivesse

Sarah Boulanger

Carole Langlois

Lidwine Wemeau-Stervinou

Thierry Perez

Benoit Wallaert

Affiliations

Soon will be listed here.

Abstract

Background: Common tests for evaluating gas exchange impairment have different strengths and weaknesses. Alveolar-to-arterial oxygen pressure difference (AaDO2) at peak exercise is a sensitive indicator but it cannot be measured repeatedly. Diffusing capacity of the lung for carbon monoxide (DLco) is measured at rest and may be too insensitive to predict the effects of exercise on gas exchange impairment. Oxygen desaturation during a 6-minute walk test (∆SpO2-6MWT) can be measured repeatedly, but its value in sarcoidosis is unknown. Here, we evaluated the ability of ∆SpO2-6MWT and DLco to predict gas exchange impairment during exercise in sarcoidosis.

Methods: This retrospective study of 130 subjects with sarcoidosis investigated the relationship between DLco, ∆SpO2-6MWT, and peak AaDO2 using correlation tests, inter-test reliability analyses, and predictive values. For the analyses of inter-test reliability and predictive values, DLco, peak AaDO2, and ∆SpO2-6MWT were considered as binary variables (normal/abnormal) according to previously defined thresholds.

Results: Correlation coefficients between DLco, ∆SpO2-6MWT, and peak AaDO2 were intermediate (0.53-0.67, P<0.0003) and Kappa coefficients were low (0.21-0.42, P=0.0003-0.02). DLco predicted (I) increased peak AaDO2 with a positive predictive value (PPV) of 66% and a negative predictive value (NPV) of 78% and (II) increased ∆SpO2-6MWT with a PPV at 36% and an NPV at 88%. Normal DLco was a good predictor of the absence of severe desaturation during the 6MWT (94% NPV) and at peak exercise during cardiopulmonary exercise test (CPET) (100% NPV). ∆SpO2-6MWT predicted peak AaDO2 increase with a PPV of 74% and an NPV of 60%.

Conclusions: In a large population of sarcoidosis patients, neither ∆SpO2-6MWT nor DLco was a good predictor of increased peak AaDO2. In contrast, normal DLco was a good predictor of the absence of severe desaturation during the 6MWT and at peak exercise during CPET.

Citing Articles

Effect of vitamin D supplementation in winter on physical performance of university students: a one-month randomized controlled trial.

Zhang X, Zhang Q, Zhang X, Gu Q, Pan J, Pei Y J Int Soc Sports Nutr. 2023; 20(1):2258850.

PMID: 37735799 PMC: 10540648. DOI: 10.1080/15502783.2023.2258850.

Frequency of peripheral blood eosinophilia and obstructive airway disease in sarcoidosis.

Rabahoglu B, Oymak F, Ketencioglu B, Tutar N, Gulmez I, Yilmaz I Turk J Med Sci. 2022; 51(6):3001-3007.

PMID: 36161645 PMC: 10734831. DOI: 10.3906sag-2007-87.

Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts.

Te H, Perlman D, Shenoy C, Steinberger D, Cogswell R, Roukoz H BMC Pulm Med. 2020; 20(1):155.

PMID: 32487134 PMC: 7268634. DOI: 10.1186/s12890-020-01191-x.

The 1-minute sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease.

Briand J, Behal H, Chenivesse C, Wemeau-Stervinou L, Wallaert B Ther Adv Respir Dis. 2018; 12:1753466618793028.

PMID: 30091679 PMC: 6088463. DOI: 10.1177/1753466618793028.

References

Boros P, Enright P, Quanjer P, Borsboom G, Wesolowski S, Hyatt R . Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J. 2010; 36(6):1315-22. DOI: 10.1183/09031936.00166809. View

Stocks J, Quanjer P . Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Respir J. 1995; 8(3):492-506. DOI: 10.1183/09031936.95.08030492. View

Mahler D, Gifford A, Waterman L, Ward J, Machala S, Baird J . Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest. 2011; 140(2):351-358. DOI: 10.1378/chest.10-2415. View

Manali E, Lyberopoulos P, Triantafillidou C, Kolilekas L, Sotiropoulou C, Milic-Emili J . MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med. 2010; 10:32. PMC: 2893122. DOI: 10.1186/1471-2466-10-32. View

Marcellis R, Lenssen A, de Vries G, Baughman R, van der Grinten C, Verschakelen J . Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?. Lung. 2012; 191(1):43-52. DOI: 10.1007/s00408-012-9432-6. View

Baughman R, Lower E . Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med. 2007; 13(5):439-44. DOI: 10.1097/MCP.0b013e328273bc2b. View

Prefaut C, Durand F, Mucci P, Caillaud C . Exercise-induced arterial hypoxaemia in athletes: a review. Sports Med. 2000; 30(1):47-61. DOI: 10.2165/00007256-200030010-00005. View

Ross R . ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167(10):1451; author reply 1451. DOI: 10.1164/ajrccm.167.10.950. View

Medinger A, Khouri S, Rohatgi P . Sarcoidosis: the value of exercise testing. Chest. 2001; 120(1):93-101. DOI: 10.1378/chest.120.1.93. View

10.

Braam A, de Haan S, Vorselaars A, Rijkers G, Grutters J, van den Elshout F . Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis. Brain Behav Immun. 2013; 33:57-64. DOI: 10.1016/j.bbi.2013.05.006. View

11.

Poulain M, Durand F, Palomba B, Ceugniet F, Desplan J, Varray A . 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest. 2003; 123(5):1401-7. DOI: 10.1378/chest.123.5.1401. View

12.

SORBINI C, Grassi V, Solinas E, MUIESAN G . Arterial oxygen tension in relation to age in healthy subjects. Respiration. 1968; 25(1):3-13. DOI: 10.1159/000192549. View

13.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

14.

Lamberto C, Nunes H, Le Toumelin P, Duperron F, Valeyre D, Clerici C . Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange. Chest. 2004; 125(6):2061-8. DOI: 10.1378/chest.125.6.2061. View

15.

. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16:1-100. View

16.

Drent M, de Vries J, Lenters M, Lamers R, Rothkranz-Kos S, Wouters E . Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol. 2003; 13(11):2462-71. DOI: 10.1007/s00330-003-1965-x. View

17.

Eaton T, Young P, Milne D, Wells A . Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005; 171(10):1150-7. DOI: 10.1164/rccm.200405-578OC. View

18.

. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by.... Am J Respir Crit Care Med. 1999; 160(2):736-55. DOI: 10.1164/ajrccm.160.2.ats4-99. View

19.

Wallaert B, Talleu C, Wemeau-Stervinou L, Duhamel A, Robin S, Aguilaniu B . Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. Respiration. 2011; 82(6):501-8. DOI: 10.1159/000330050. View

20.

Holland A, Spruit M, Troosters T, Puhan M, Pepin V, Saey D . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1428-46. DOI: 10.1183/09031936.00150314. View